Triparanol

A synthetic cholesterol-lowering drug

Triparanol
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Triparanol was a cholesterol-lowering drug that was developed in the 1950s and marketed in the early 1960s. It was withdrawn from the market due to adverse effects.

History

Triparanol was introduced as a cholesterol-lowering agent in the early 1960s. It was marketed under the brand name MER/29. The drug was one of the first synthetic agents used to lower cholesterol levels in the blood.

Mechanism of Action

Triparanol works by inhibiting the enzyme desmosterol _24-reductase, which is involved in the biosynthesis of cholesterol. This inhibition leads to the accumulation of desmosterol, a precursor in the cholesterol synthesis pathway, and a reduction in cholesterol levels.

Adverse Effects

Despite its effectiveness in lowering cholesterol, Triparanol was associated with several adverse effects. Patients reported side effects such as cataracts, alopecia, and skin disorders. These adverse effects were significant enough to lead to the withdrawal of the drug from the market.

Withdrawal from the Market

Due to the severe side effects, Triparanol was withdrawn from the market in 1962. The withdrawal highlighted the importance of thorough drug testing and monitoring for adverse effects.

Legacy

The case of Triparanol is often cited in discussions about drug safety and the importance of post-marketing surveillance. It serves as a reminder of the potential risks associated with new pharmaceuticals and the need for rigorous clinical trials.

Related pages

• Cholesterol
• Desmosterol
• Drug safety

Triparanol

• 

  Triparanol